Genetic Technologies Ltd (GENE) Stock Fundamental Analysis

NASDAQ:GENE • US37185R4065

0.765 USD
-0.02 (-1.92%)
At close: Oct 16, 2024
0.75 USD
-0.02 (-1.96%)
After Hours: 10/16/2024, 9:36:40 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Overall GENE gets a fundamental rating of 1 out of 10. We evaluated GENE against 58 industry peers in the Life Sciences Tools & Services industry. GENE may be in some trouble as it scores bad on both profitability and health. GENE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • GENE had negative earnings in the past year.
  • In the past year GENE has reported a negative cash flow from operations.
  • GENE had negative earnings in each of the past 5 years.
  • In the past 5 years GENE always reported negative operating cash flow.
GENE Yearly Net Income VS EBIT VS OCF VS FCFGENE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • GENE's Return On Assets of -194.25% is on the low side compared to the rest of the industry. GENE is outperformed by 98.21% of its industry peers.
  • The Return On Equity of GENE (-656.53%) is worse than 92.86% of its industry peers.
Industry RankSector Rank
ROA -194.25%
ROE -656.53%
ROIC N/A
ROA(3y)-102.54%
ROA(5y)-75.74%
ROE(3y)-268.4%
ROE(5y)-176.61%
ROIC(3y)N/A
ROIC(5y)N/A
GENE Yearly ROA, ROE, ROICGENE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

  • GENE has a Gross Margin (50.94%) which is in line with its industry peers.
  • The Profit Margin and Operating Margin are not available for GENE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GENE Yearly Profit, Operating, Gross MarginsGENE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • GENE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • GENE has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for GENE has been reduced compared to 5 years ago.
  • Compared to 1 year ago, GENE has a worse debt to assets ratio.
GENE Yearly Shares OutstandingGENE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
GENE Yearly Total Debt VS Total AssetsGENE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • GENE has an Altman-Z score of -40.90. This is a bad value and indicates that GENE is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -40.90, GENE is not doing good in the industry: 96.43% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 0.36 indicates that GENE is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.36, GENE is in line with its industry, outperforming 46.43% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Altman-Z -40.9
ROIC/WACCN/A
WACC10.02%
GENE Yearly LT Debt VS Equity VS FCFGENE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

  • GENE has a Current Ratio of 0.88. This is a bad value and indicates that GENE is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.88, GENE is doing worse than 91.07% of the companies in the same industry.
  • A Quick Ratio of 0.83 indicates that GENE may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.83, GENE is doing worse than 87.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.83
GENE Yearly Current Assets VS Current LiabilitesGENE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • GENE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.74%, which is quite good.
  • GENE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -11.76%.
  • GENE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 213.18% yearly.
EPS 1Y (TTM)19.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.06%
Revenue 1Y (TTM)-11.76%
Revenue growth 3Y299.13%
Revenue growth 5Y213.18%
Sales Q2Q%-18.23%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GENE Yearly Revenue VS EstimatesGENE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • GENE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GENE Price Earnings VS Forward Price EarningsGENE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GENE Per share dataGENE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • GENE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

Genetic Technologies Ltd

NASDAQ:GENE (10/16/2024, 9:36:40 PM)

After market: 0.75 -0.02 (-1.96%)

0.765

-0.02 (-1.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-29
Earnings (Next)N/A
Inst Owners2.68%
Inst Owner Change571.28%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.58M
Revenue(TTM)7.66M
Net Income(TTM)-12.02M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.51
P/FCF N/A
P/OCF N/A
P/B 2.12
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.74
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-1.91
OCFYN/A
SpS1.51
BVpS0.36
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -194.25%
ROE -656.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.94%
FCFM N/A
ROA(3y)-102.54%
ROA(5y)-75.74%
ROE(3y)-268.4%
ROE(5y)-176.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.24
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 0.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.88
Quick Ratio 0.83
Altman-Z -40.9
F-Score4
WACC10.02%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)0.69%
Cap/Sales(5y)201.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.06%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.76%
Revenue growth 3Y299.13%
Revenue growth 5Y213.18%
Sales Q2Q%-18.23%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.45%
OCF growth 3YN/A
OCF growth 5YN/A

Genetic Technologies Ltd / GENE FAQ

What is the ChartMill fundamental rating of Genetic Technologies Ltd (GENE) stock?

ChartMill assigns a fundamental rating of 1 / 10 to GENE.


What is the valuation status for GENE stock?

ChartMill assigns a valuation rating of 0 / 10 to Genetic Technologies Ltd (GENE). This can be considered as Overvalued.


What is the profitability of GENE stock?

Genetic Technologies Ltd (GENE) has a profitability rating of 0 / 10.


What is the financial health of Genetic Technologies Ltd (GENE) stock?

The financial health rating of Genetic Technologies Ltd (GENE) is 1 / 10.